Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Pharm Pharmacol ; 70(8): 1069-1077, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29882598

ABSTRACT

OBJECTIVES: To determine the Km , Vmax , cofactor, activator and inhibitor requirements of human cysteine dioxygenase and S-carboxymethyl-l-cysteine S-oxygenase with respect to both l-Cysteine and S-carboxymethyl-l-cysteine as substrates. METHODS: In vitro human hepatic cytosolic fraction enzyme assays were optimised for cysteine dioxygenase activity using l-Cysteine as substrate and the effect of various cofactors, activators and inhibitors on the S-oxidations of both l-Cysteine and S-carboxymethyl-l-cysteine were investigated. KEY FINDINGS: The results of the in vitro reaction phenotyping investigation found that although both cysteine dioxygenase and S-carboxymethyl-l-cysteine S-oxygenase required Fe2+ for catalytic activity both enzymes showed considerable divergence in cofactor, activator and inhibitor specificities. Cysteine dioxygenase has no cofactor but uses NAD+ and NADH(H+ ) as pharmacological chaperones and is not inhibited by S-carboxymethyl-l-cysteine. S-carboxymethyl-l-cysteine S-oxygenase requires tetrahydrobiopterin as a cofactor, is not activated by NAD+ and NADH(H+ ) but is activated by l-Cysteine. Additionally, the sulfydryl alkylating agent, N-ethylmaleimide, activated carboxymethyl-l-cysteine S-oxygenase but inhibited cysteine dioxygenase. CONCLUSIONS: Human hepatic cytosolic fraction cysteine dioxygenase activity is not responsible for the S-oxidation of the substituted cysteine, S-carboxymethyl-l-cysteine.


Subject(s)
Carbocysteine/metabolism , Cysteine Dioxygenase/metabolism , Cysteine/metabolism , Cytosol/metabolism , Liver/metabolism , Cytosol/enzymology , Female , Humans , In Vitro Techniques , Liver/ultrastructure , Oxidation-Reduction , Substrate Specificity
2.
J Pharm Pharmacol ; 56(8): 993-1000, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15285843

ABSTRACT

The identity of the enzyme(s) responsible for the S-oxidation of the mucoactive drug S-carboxymethyl-L-cysteine (SCMC) is unknown but the protein(s) are a susceptibility factor for a number of chronic degenerative diseases. The structural similarities between the amino acid L-cysteine and SCMC have raised the possibility that cysteine dioxygenase (CDO) may be responsible for this biotransformation reaction. Both CDO and SCMC S-oxygenase were found to require Fe2+ for enzymatic activity, and both enzyme activities were inhibited by Fe2+ and Fe3+ chelators. However, sulphydryl group modification of the enzymes resulted in the activation of the S-oxidation of SCMC but inhibition of the S-oxidation of L-cysteine. When the two enzyme activities were quantified in 20 female hepatic cytosolic fractions no linear correlation in the production of their respective metabolites was seen. The results of this investigation indicate that CDO is not responsible for the S-oxidation of SCMC in the rat.


Subject(s)
Carbocysteine/metabolism , Dioxygenases/metabolism , Liver/drug effects , Animals , Biotransformation/drug effects , Cells, Cultured , Chelating Agents/pharmacology , Cysteine/pharmacology , Cysteine Dioxygenase , Cytosol/drug effects , Cytosol/enzymology , Dioxygenases/pharmacology , Drug Interactions , Female , Liver/enzymology , Oxidation-Reduction/drug effects , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL